SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pete Holm who wrote (295)2/15/1997 10:55:00 AM
From: Brad C. Dunlap   of 6136
 
Hi Pete, I don't have a balance sheet in front of me but basically book value is assets minus liablilaties divided by shares outstanding ,or shareholderes equity divided by shares outstanding . Its safe to assume the book value of AGPH is relatively low compared to the current mkt price but this is true in most all biotechs and for sure the tremendous appreciation in the past year has nothing to do with the price to book value. I think others on this thread have commented on the market capitilization[shs outstanding times current price] relative to the potential earnings power and value of AGPH product pipeline. This is where the dabate begins as to what valuation or price should AGPH currently be trading. I think Richard and others have done an excellent job of analyzing the pros and cons and potential competitive threat and when all is considered this is one exciting company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News